Latest Conference Articles

New research presented at CHEST 2024 highlights ensifentrine’s effectiveness in improving lung function, symptoms, and quality of life for COPD patients, regardless of disease severity.

HCPLive spoke with Maguire about the benefits of acetylcholine and muscarinic receptors for the treatment of schizophrenia.

APAC President Laura Ross, PA-C, shares insights from the RhAPP conference, discussing autoimmune disease, cardiovascular risks, and the importance of interdisciplinary care.

These data were presented at EADV 2024 by UCB, with presenters highlighting positive long-term efficacy findings for bimekizumab among patients with plaque psoriasis.

Rahul Aggarwal, MD, discusses how the VICTORION-1 PREVENT trial eligibility criteria apply to the general US population.

The HCPLive Cardiology month in review for September 2024 spotlights ESC Congress 2024, Family Heart Global Summit, pipeline updates, and more!

This segment of Marghoob’s interview featured a discussion of pigmented lesion identification and use of technology such as AI.

Steve Nissen, MD, discusses how the cardiology community needs to learn from previous mistakes in uptake of LDL-C lowering therapies as it approaches an age of Lp(a)-lowering agents.

In this interview, Marghoob highlights some of the biggest diagnostic challenges faced by dermatologists and other providers when it comes to pigmented lesions.

New data presented by Sun Pharma at EADV 2024 highlight the impact of deuruxolitinib 8 mg treatment of adults with severe alopecia areata.

Bau explains the challenges of using MELD to determine liver transplant referrals and other complexities of the evaluation process.

A comparison of the PALISADE and BALANCE trials, with commentary from a leading cardiologist, as the community nears a potential approval in FCS.

HCPLive spoke to Rodriguez, MD, MPH, about implementing AI in cardiology care.

Crimaldi reviews key considerations for the diagnosis and management of bowel ischemia, diverticulitis, and small bowel obstructions in GI inpatients.

In an interview O’Donoghue talked about emerging RNA therapies for Lp(a) in phase 2 and 3 trials.

These new data were announced by Celldex Therapeutics regarding the sustained and deepening efficacy of barzolvolimab treatment of chronic spontaneous urticaria.

Christie Ballantyne, MD, discusses non-statin therapies, both approved and in development, for managing dyslipidemias from the floor of the 2024 Family Heart Global Summit.

The DELTA trial results on delgocitinib cream as a topical option for CHE were presented at the EADV Congress 2024.

Temtokibart showed similar efficacy to dupilumab in treating moderate-to-severe atopic dermatitis, with faster skin hydration improvements in a phase 2a trial.

These new data on treatment of atopic dermatitis and prurigo nodularis were presented by Galderma at the European Academy of Dermatology & Venereology Congress.

These new findings were released by Arcutis Biotherapeutics and presented at the European Academy of Dermatology & Venereology Congress.

A Q&A with Nihar Desai, MD, on the PROMPT-Lipid trial and the potential of advancing technology for improving patient care in pragmatic ways.

Benjamin Scirica, MD, discusses the importance of team-based care and leveraging technology to optimize the management of cardiovascular risk factors.

Adding semaglutide to standard hidradenitis suppurative therapies achieved improvements in quality of life and fewer disease-related flares.

The ESS device, leveraging artificial intelligence, may allow for enhanced decision making among nurse practitioners as well as physician assistants evaluating patients for skin cancer.

Nihar Desai, MD, discusses the results of the PROMPT-Lipid trial while on-site at the 2024 Family Heart Global Summit.

Laurence Sperling, MD, discusses his presentation from the 2024 Family Heart Global Summit examining public health efforts for prevention of cardiovascular disease.

These data from the DISCREET study highlight the impact of apremilast on men and women with genital psoriasis.

A handheld tool improved skin cancer detection in primary care, increasing diagnostic sensitivity to 96.3% compared to 83.9% without the device.

Calabrese discussed the multi-faceted role of viral infections in the field of rheumatology ahead of the 2024 CCR West meeting.